Literature DB >> 19004621

Association of COX2 functional polymorphisms and the risk of vitiligo in Chinese populations.

Miao Li1, Ying Gao, Chunying Li, Ling Liu, Kai Li, Lin Gao, Gang Wang, Zhengdong Zhang, Tianwen Gao.   

Abstract

BACKGROUND: Cyclooxygenase-2 (COX2) plays an important role in the production of prostaglandin E2 (PGE2), which is made by epidermal keratinocytes in response to ultraviolet radiation (UVR). PGE2 is important for the proliferation and melanogenesis of epidermal melanocytes, the loss of which leads to vitiligo. COX2-1195A>G, -765G>C, and -8473T>C polymorphisms may influence the mRNA levels of COX2 and affect the production of PGE2 subsequently. Therefore, we supposed that these polymorphisms may be associated with vitiligo.
OBJECTIVE: The aim of the study was to elucidate the association between three functional COX2 polymorphisms and the risk of vitiligo.
METHODS: This was a hospital-based, case-control study of 755 vitiligo patients and 774 vitiligo-free controls who were frequency matched by age and sex. We genotyped COX2-1195A>G, -765G>C, and -8473T>C polymorphisms by using PCR-restriction fragment length polymorphism (RFLP) method and assessed their respective associations with the risk of vitiligo in Han Chinese populations.
RESULTS: We found a statistically significant increased risk of vitiligo to be associated with the COX2-1195 G variant allele (p=0.004). Significantly higher vitiligo risks were found among subgroups with these characteristics: age >20 years, male, active, nonsegmental vitiligo, and onset age >20 years. In addition, the interaction between COX2-1195 and COX2-8473 was statistically significant (p=0.004).
CONCLUSION: For the first time, we provide evidence that functional polymorphisms in the COX2 gene may influence the risk of vitiligo in Han Chinese populations, suggesting new clues that help to clarify the pathogenesis of vitiligo. Larger studies are needed to verify these findings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004621     DOI: 10.1016/j.jdermsci.2008.09.010

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  7 in total

1.  Update on the genetics characterization of vitiligo.

Authors:  Hani A Al-Shobaili
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

2.  COX-1 and COX-2 polymorphisms in susceptibility to cerebral palsy in very preterm infants.

Authors:  Helena Kapitanović Vidak; Tina Catela Ivković; Zoran Vidak; Sanja Kapitanović
Journal:  Mol Neurobiol       Date:  2016-01-19       Impact factor: 5.590

3.  Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP.

Authors:  Stanca A Birlea; Ying Jin; Dorothy C Bennett; Deborah M Herbstman; Margaret R Wallace; Wayne T McCormack; E Helen Kemp; David J Gawkrodger; Anthony P Weetman; Mauro Picardo; Giovanni Leone; Alain Taïeb; Thomas Jouary; Khaled Ezzedine; Nanja van Geel; Jo Lambert; Andreas Overbeck; Pamela R Fain; Richard A Spritz
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

Review 4.  Modern vitiligo genetics sheds new light on an ancient disease.

Authors:  Richard A Spritz
Journal:  J Dermatol       Date:  2013-05       Impact factor: 4.005

5.  A study of the association of glutathione S-transferase M1/T1 polymorphisms with susceptibility to vitiligo in Egyptian patients.

Authors:  Dalia Gamal Aly; Samar Abdallah Salem; Khalda Sayed Amr; Mahmoud Fawzy Abd El-Hamid
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

6.  Association of COX-2 Promoter Polymorphisms -765G/C and -1195A/G with Migraine.

Authors:  Elahe Mozaffari; Abbas Doosti; Asghar Arshi; Mostafa Faghani
Journal:  Iran J Public Health       Date:  2016-12       Impact factor: 1.429

7.  Polygonum multiflorum Thunb. Extract Stimulates Melanogenesis by Induction of COX2 Expression through the Activation of p38 MAPK in B16F10 Mouse Melanoma Cells.

Authors:  Donghee Kim; Hyo-Jin Kim; Hee-Sook Jun
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-25       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.